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TO THE EDITOR
Nevus spilus is a descriptive term used
to denote any cutaneous lesion with
a cafe´-au-lait macular background and
superimposed on more pigmented areas.
Small single nevus spilus are relatively
common, and they have recently been
described to be due to somatic activating
HRAS mutations (Sarin et al., 2014).
Larger superficial lesions with small
superimposed junctional nevi in associ-
ation with phakomatosis pigmentokera-
totica have also been found to contain
HRAS mutations (Groesser et al., 2013).
However, another nevus spilus–type
phenotype has also been well described
in which large cafe´-au-lait macules have
superimposed lesions that are indistin-
guishable both clinically and histopatho-
logically from medium/large congenital
melanocytic nevi (CMN), exhibit a wide
variety of colors and sizes (Schaffer et al.,
2001a, b), and continue to develop post-
natally in many cases. This is termed
nevus spilus–type CMN. In our experi-
ence, there may be delayed appearance
of the cafe´-au-lait background after birth,
but the lesion is still usually predictable
on the basis of clustering of many CMN
in one anatomical area. Smaller separate
lesions in the same individual are often
indistinguishable clinically from cafe´-
au-lait macules, and are so faint that
they can be easily missed (Figure 1).
Our primary aim in this study was to
look for the genetic basis of this defined
phenotypic subset of CMN, in the con-
text of the recent discovery that NRAS
Q61K and Q61R mutations are the cause
of most causes of multiple CMN (Kinsler
et al., 2013b). In particular, we were
interested in determining the mutation in
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Figure 1. Clinical images of nevus spilus–type CMN in six different patients. The cafe´-au-lait macule background is often invisible at birth. Two separate lesions
are indicated in one patient. CMN, congenital melanocytic nevi. Written consent was obtained for publication of all photographs.
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Abbreviation: CMN, congenital melanocytic nevus or nevi
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the background macular portion of the
nevus spilus–type CMN, working on the
hypothesis that this could be the ‘‘first
hit’’ in a two-hit model of nevogenesis.
These studies were approved by the
appropriate Research Ethics Committee,
written consent was taken from partici-
pants, and the Declaration of Helsinki
Principles protocols were followed. A
blood sample and skin biopsies of both
the cafe´-au-lait macule background and
a banal superimposed CMN were taken
from three children with large nevus
spilus–type CMN, from a total of 17
patients from our combined practices
(patients 5, 12, and 13 in Supplemen-
tary Table S1 online), and DNA was
extracted directly by standard methods.
Whole-exome sequencing using Nextera
library preparation and an ABI Hi-Seq
bioanalyser was undertaken on all three
samples from two patients, and data were
analyzed using an in-house pipeline
designed for somatic mosaicism. The
principal governing analysis was to look
for a mutation present in the cafe´-au-lait
that was not present in the blood, and a
further mutation in the CMN not present
in the cafe´-au-lait or the blood.
In all, 1,991,478 variants were called
automatically in the overlying CMN,
affecting 20,693 genes. After filtering,
the sequencing files of 133 variants in
39 genes were reviewed manually. A
single mutation was found in the cafe´-
au-lait macule and the superimposed
CMN, with no further mutation con-
firmed despite extensive analysis. These
mutations were missense activating
mutations in NRAS in the skin, absent
from the blood, and this pattern of
somatic mosaicism was confirmed in
the third patient by Sanger sequencing.
The mutations, however, are undes-
cribed so far in typical CMN, being
1:115256528 c.183A4C p.Q61H (two
patients, Figure 2) and 1:115258745
c.37G4C p.G13R. Both mutations have
Figure 2. Sequencing results showing NRAS mutation. Next-generation sequencing reads of blood (upper left), cafe´-au-lait macule (upper centre), and overlying
CMN (upper right) from the same patient showing mutation NRAS c.183A4C p.Q61H. Note the absence of mutation in the blood, and the much lower
percentage of mosaicism in the cafe´-au-lait than the CMN, as would be expected from the number of affected cells in a biopsy sample. Sanger sequencing (below)
confirmation of the heterozygous pQ61H mutation in CMN. CMN, congenital melanocytic nevi.
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been described at a somatic level in non-
CMN-related malignant melanoma
(Forbes et al., 2008). Independently, a
fourth patient (patient 17, Supplementary
Table S1 online) had targeted exon
capture of two skin samples, and analy-
sis also revealed only the same NRAS
p.Q61H mutation in both the cafe´-au-
lait macule and the superimposed CMN.
In conclusion, nevus spilus–type
CMN are a phenotypically and geno-
typically distinct variant of CMN, and
are phenotypically and genotypically
distinct from nevus spilus maculosus
and papulosus due to HRAS mutations
(Groesser et al., 2013; Sarin et al., 2013).
This further extends the exquisite
mutation specificity of the newly
characterized mosaic RASopathies. We
found no evidence of a second mutation
to explain the superimposed nevi on the
macular background. It is, however,
possible that there could be a mutation
that does not appear pathogenic to us
and to the analysis pipelines at the
present time. Alternatively, there could
be either a translocation that does not
disrupt exonic DNA sequence, or a
growth-promoting copy number change,
although CMN have previously been
documented as having few such
changes on array comparative genomic
hybridization (Bastian et al., 2002). The
data at the moment suggest that only
one sequence-level mutation occurs,
and that these specific NRAS mutations
are sufficient to cause cafe´-au-lait
macular pigmentation, which can lead
to macroscopic nevus formation over
time. Other experimental evidence
supports that nevi can evolve in this
way, from a cell or collection of cells
in the skin not visible to the naked eye,
as nevus cells have been found in normal
skin in patients with acquired melano-
cytic nevi and typical CMN (Dadzie
et al., 2008; Kinsler et al., 2013a).
It is important to note for clinical
management that malignant melanoma
has been described in patients with
nevus spilus–type CMN (Kinsler et al.,
2009), and on current knowledge we
would consider nevus spilus–type CMN
patients at the same risk of malignancy
as other genotypes. Similarly, although
interestingly none of the 17 patients
described here have neurological abnor-
malities on magnetic resonance imaging
scan (Supplementary Table S1 online),
these numbers are too small to draw any
conclusions about a possible low risk of
neurological phenotype. Management
of nevus spilus–type CMN should there-
fore be the same as for other CMN.
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